![Beverly Moy (@beverlymoy) 's Twitter Profile](https://pbs.twimg.com/profile_images/822841562434510849/7RGkqXrR_200x200.jpg)
Beverly Moy
@beverlymoy
Medical Oncologist, Director of Cancer Equity & Clinical Director of Breast Oncology at Mass General Hospital; Professor, Harvard Medical School. Views my own.
ID: 1463076127
27-05-2013 20:19:42
495 Tweet
1,1K Followers
288 Following
![Beverly Moy (@beverlymoy) 's Twitter Profile Photo Beverly Moy (@beverlymoy) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/822841562434510849/7RGkqXrR_200x200.jpg)
Kevin Kalinsky, MD, MS, FASCO presents postMONARCH, the first trial showing benefit of continuing CDK4/6 inhibition after progression on prior CDK. Congrats to investigators, including senior author Mass General Cancer Center MGH Breast Oncology Seth Wander #ASCO24
![Beverly Moy (@beverlymoy) on Twitter photo <a href="/KalinskyKevin/">Kevin Kalinsky, MD, MS, FASCO</a> presents postMONARCH, the first trial showing benefit of continuing CDK4/6 inhibition after progression on prior CDK. Congrats to investigators, including senior author <a href="/MGHCancerCenter/">Mass General Cancer Center</a> <a href="/MGHBreastOnc/">MGH Breast Oncology</a> Seth Wander #ASCO24 <a href="/KalinskyKevin/">Kevin Kalinsky, MD, MS, FASCO</a> presents postMONARCH, the first trial showing benefit of continuing CDK4/6 inhibition after progression on prior CDK. Congrats to investigators, including senior author <a href="/MGHCancerCenter/">Mass General Cancer Center</a> <a href="/MGHBreastOnc/">MGH Breast Oncology</a> Seth Wander #ASCO24](https://pbs.twimg.com/media/GPA2vzRXMAAbie1.jpg)